, Tracking Stock Market Picks
Enter Symbol:
Mckesson Corporation (MCK) [hlAlert]

up 214.66 %

Mckesson Corporation (MCK) upgraded to Buy by Standpoint Research

Posted on: Monday,  Aug 2, 2010  4:25 PM ET by Standpoint Research

Standpoint Research rated Buy Mckesson Corporation (NYSE: MCK) on 08/02/2010, when the stock price was $63.20. Since
then, Mckesson Corporation has gained 214.67% as of 01/12/2016's recent price of $198.87.
If you would have followed this Standpoint Research's recommendation on MCK, you would have gained 214.66% of your investment in 1989 days.

McKesson Corporation (McKesson) provides supply, information and care management products and services across the healthcare industry. The Company operates through two segments: The McKesson Distribution Solutions segment and The McKesson Technology Solutions segment. The McKesson Distribution Solutions segment distributes ethical drugs, medical-surgical supplies and equipment, and health and beauty care products throughout North America. This segment also provides specialty pharmaceutical solutions for biotech and pharmaceutical manufacturers, sells pharmacy software and provides consulting, outsourcing and other services. The McKesson Technology Solutions segment delivers enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions, pharmacy automation for hospitals, as well as connectivity, outsourcing and other services.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/2/2010 4:25 PM Buy
as of 12/31/2010
1 Week up  3.31 %
1 Month up  14.56 %
3 Months up  18.50 %
1 YTD up  27.00 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/24/2010 1:25 PM Hold
1/19/2010 8:25 AM Buy

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy